Expert Interview
A look at CART-T administration - Discussing the challenges and opportunities institutions face in administering CAR-T
Ticker(s): LEGN, NVS, BMY, GILD, JNJInstitution: Stanford
Distinguished hematologist and Professor of Medicine at Stanford University, where he served as Chief of the Division of Blood and Marrow Transplantation.
Administers 200 CAR T cell therapies per year, increasing at 10-15% per year.
Research focuses on cellular immunology, particularly graft-versus-host and graft-versus-tumor reactions, and has authored over 265 peer reviewed publications.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
